$50.41−0.04 (−0.08%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE · USD
$50.410.00 (0.00%)
After hours: Nov 16, 2026, 4:47 PM ET
GSK Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineSteady: revenue compounds ~7.1%/yr (FY21→FY25), net margin 19.3%.
The four lines that matter · FY21–FY25
Revenue ($B)▲11.8%
43.9
FY21→FY25CAGR +7.1%/yr
Net income ($B)▲128.9%
8.5
one-off year: see footnoteCAGR +5.3%/yr
Free cash flow ($B)▲97.7%
8.8
FY21→FY25CAGR —
Diluted EPS▲139.7%
1.87
buyback-liftedCAGR +3.7%/yr
What the receipts whisper · what a headline number hides
Share count
−19.9%
5.4bn → 4.3bn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
Capex
$1.8B
−51.5% YoY in FY25 · 4.1% of revenue.
Returns vs FCF
66%
$5.8B returned vs $8.8B of FCF in FY25. Buybacks + dividends covered by cash flow.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($B)
19¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 66.9% → 72.4%. Net margin 19.3% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | FY25 † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 43,927.3 | 43,927.3 | 39,285.9 | 38,647.0 | 35,414.6 | 33,339.6 | ▲11.8% | +7.1% |
Cost of revenue | 12,125.2 | 12,125.2 | 11,329.0 | 10,914.4 | 11,538.4 | 11,020.0 | ▲7.0% | +2.4% |
Gross profit | 31,802.2 | 31,802.2 | 27,956.9 | 27,732.6 | 23,876.2 | 22,319.5 | ▲13.8% | +9.3% |
Research & development | 10,118.9 | 10,118.9 | 8,014.7 | 7,930.0 | 6,627.9 | 6,775.6 | ▲26.3% | +10.5% |
Selling, general & admin | 12,220.6 | 12,220.6 | 13,791.9 | 11,959.3 | 10,110.9 | 9,544.5 | ▼11.4% | +6.4% |
Total operating expenses | 22,318.0 | 22,318.0 | 23,714.8 | 20,350.6 | 17,022.5 | 17,000.5 | ▼5.9% | +7.0% |
Operating incomefeeds ROC rank | 10,666.2 | 10,666.2 | 5,034.7 | 8,595.2 | 7,769.1 | 5,881.9 | ▲111.9% | +16.0% |
Other income, net | −714.0 | −714.0 | −681.1 | −867.8 | −972.2 | −1,023.3 | — | — |
Pretax income | 9,952.1 | 9,952.1 | 4,353.6 | 7,727.4 | 6,796.9 | 4,858.6 | ▲128.6% | +19.6% |
Income tax | 1,495.3 | 1,495.3 | 658.6 | 963.4 | 853.8 | 112.0 | ▲127.0% | +91.1% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 8,456.8 | 8,456.8 | 3,694.9 | 6,764.0 | 18,865.5 | 6,879.6 | ▲128.9% | +5.3% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 1.87 | 1.87 | 0.78 | 1.53 | 11.99 | 1.61 | ▲139.7% | +3.7% |
Diluted shares (bn) | 4.32 | 4.32 | 4.31 | 4.31 | 4.31 | 5.39 | ▲0.0% | −5.4% |
| Margins | ||||||||
Gross margin63rd pct in Healthcare | 72.4% | 72.4% | 71.2% | 71.8% | 67.4% | 66.9% | ▲1.2pp | +5.5pp |
Operating margin | 24.3% | 24.3% | 12.8% | 22.2% | 21.9% | 17.6% | ▲11.5pp | +6.6pp |
Net margin84th pct in Healthcare | 19.3% | 19.3% | 9.4% | 17.5% | 53.3% | 20.6% | ▲9.8pp | −1.4pp |
† FY25 = fiscal 2025, through 2025-12-31; the trailing year is not available.FY21 effective tax rate was 2% vs a 13% norm for this window, likely a one-time item; see the filing.
5 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-06 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was GSK's revenue last fiscal year?
GSK reported revenue of $43.9B in fiscal 2025, up 11.8% from fiscal 2024.
What was GSK's net income?
GSK reported net income of $8.5B in fiscal 2025, a net margin of 19.3%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

